# Keiretsu Capital

> Keiretsu Capital is a VC fund backing Health Care and Biotechnology. See 182 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seattle, United States
- Total investments: 182
- Last investment: Aug 2024
- Lead investor: 2%
- Fund size: $3.7M
- Last fund: Dec 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/keiretsu-capital
- X (Twitter): https://twitter.com/keiretsucapital
- Website: http://www.keiretsucapital.com/
- Facebook: https://www.facebook.com/keiretsucapital?ref=aymt_homepage_panel

Keiretsu Capital is a VC fund in Seattle focused on Health Care and Biotechnology. Keiretsu Capital provides access to proprietary deal flow to its investors. Keiretsu Capital works to increase the value of investments undertaken by Keiretsu Forum members by assisting in the successful presentation of the portfolio companies to investors including syndicate partners, venture capitalists, corporate investors, and the publicmarkets.It aims to provide significant capital appreciation through investment in high quality emerging companies that have been funded by the world’s largest angel investor network, Keiretsu Forum, as well as other top tier angel groups.

## Contacts

5 contacts available for Keiretsu Capital. Shizune tracks 4 team members at Keiretsu Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/keiretsu-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $700k–$2.5M |
| Series A | $1.2M–$12M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 39 | 21% |
| Biotechnology | 27 | 15% |
| Medical | 22 | 12% |
| Software | 20 | 11% |
| Medical Device | 19 | 10% |

174 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 37 | 20% |
| Convertible Note | 29 | 16% |
| Seed | 28 | 15% |
| Funding Round | 27 | 15% |
| Series B | 12 | 7% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 103 | 57% |
| Canada | 8 | 4% |
| India | 2 | 1% |
| Israel | 1 | 1% |
| Sweden | 1 | 1% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kevin Sterling | Keiretsu Capital Senior Advisor Network | 0 | https://shizune.co/investors/profile/kevin-sterling |
| Mary Jo Potter | General Partner | 0 | https://shizune.co/investors/profile/mary-jo-potter |
| Matthew Le Merle | Managing Partner & Co-founder | 2 | https://shizune.co/investors/profile/matthew-le-merle |
| Nathan McDonald | Managing Partner and CEO | 84 | https://shizune.co/investors/profile/nathan-mcdonald |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MiClient | Easy and Smart way to manage your Proposals and Clients An effortless way to Deliver Winning Proposals, Automate Client On-boarding and improve Payment Collection experience for Service sector. We Provides Proposal Management System + Online Client On-boarding Solution. | $464.9K | Seed | Aug 12, 2024 |  |
| Healionics | Healionics has applied its expertise in synthetic biomaterials to develop a novel vascular graft (artificial blood vessel) that, unlike existing grafts, remains open to blood flow long-term without need for costly interventions. Its first commercial application will be as a more reliable means of vascular access for dialysis patients, with asubsequent application to treat peripheral artery disease. We have great results in multiple controlled animal studies, a large patent portfolio, established production capacity, and are ready to begin human studies later this year in preparation for market launch.Near-Term Problem / Market Opportunity: Vascular Access for Dialysis Kidney failure patients need to have their blood filtered 3 times per week via dialysis. This removes waste from the blood, which would otherwise cause them to die. However, current methods for repeatedly accessing the bloodstream for dialysis are unreliable. This problem is a huge contributor to the $50 billion per year that the U.S. spends on dialysis patients (7% of Medicare’s entire budget!). A vascular graft is often implanted under the skin (connecting an artery to a vein) to create an access site with sufficient bloodflow for dialysis -- but existing grafts tend to occlude quickly, requiring repeated expensive interventions to keep them open.Solution: STARgraft Because our vascular graft remains open to blood flow much longer than existing grafts, it can potentially satisfy a severe unmet clinical need for ready-to-use, safe, long-term dialysis access, while substantially reducing costs, illness and death rate among dialysis patients.Product Pipeline We have additional products in development, including an implantable port which will allow needle-free dialysis. Eliminating the use of needles would further reduce cost and illness among dialysis patients, and allow them to perform dialysis in the convenience of their own home. In addition, our platform STAR biomaterial can improve the performance of a wide range of implantable devices via its remarkable ability to prevent both infection and scar tissue. We currently have two corporate-funded development contracts to explore STAR material’s use in multiple other device applications. | $5.5M | Series A | Nov 07, 2023 |  |
| NuvOx Therapeutics | NuvOx Pharma develops a platform for drugs that upon intravenous injection, flow through the bloodstream arriving first at the lungs to pick up oxygen and finally to hypoxic tissue where they passively deliver the oxygen. Indications for NuvOx's drug include Stroke (Phase II ready), Oncology (Phase II ready), and Sickle Cell Crisis (Phase Ibready). | $7M | Convertible Note | Sep 27, 2023 |  |
| CurvaFix | CurvaFix is an emerging medical device company based in the Seattle area. We are developing a novel solution for an unmet need in orthopedic trauma. | $39M | Series C | Jul 14, 2023 |  |
| Clensta | Clensta is a biotechnology start-up to improve the National Hygiene condition whilst addressing the aspect of water conservation. Clensta is an Indian startup and in association with IIT Delhi, works to create innovative healthcare solutions to make hygiene accessible for anyone, anytime, and anywhere. Driven by their aim to create products thatpromote complete cleaning solutions without water. | $8.9M |  | Jul 10, 2023 |  |
| Clensta | Clensta is a biotechnology start-up to improve the National Hygiene condition whilst addressing the aspect of water conservation. Clensta is an Indian startup and in association with IIT Delhi, works to create innovative healthcare solutions to make hygiene accessible for anyone, anytime, and anywhere. Driven by their aim to create products thatpromote complete cleaning solutions without water. | $9.1M | Series B | Jul 10, 2023 |  |
| Another Tomorrow | Launched in January 2020, Another Tomorrow is a tech-enabled, digitally-native, sustainable luxury brand reinventing fashion in service of our shared tomorrow. Their digitized product eco-system provides consumer-facing transparency, authenticated resale and an architecture for further innovation. Marketplace extensions are on the roadmap for 2H2021.They are the first, and currently the only, luxury fashion brand to be B-Corp certified.You can find some of their recent press here: NYTimes, Bloomberg, Vogue (retail coverage), Vogue (Op-Ed), The Cut, Fast Company (honorable mention), Forbes, Business of Fashion and the WSJ. |  | Series A | May 19, 2023 |  |
| EarthGrid PBC | EarthGrid™ is developing the world’s first way to tunnel, trench, and excavate using our patented plasma tunnel-boring technology. Compared to traditional tunneling, trenching, and excavation methods, this technology has the potential to: – Work exponentially faster
 – Save dramatically in costs Our machines will employ high-power plasma torchesthat can vaporize and break up rock, clay, and obstacles into small fragments (known as spallation). |  |  | May 15, 2023 |  |
| EarthGrid PBC | EarthGrid™ is developing the world’s first way to tunnel, trench, and excavate using our patented plasma tunnel-boring technology. Compared to traditional tunneling, trenching, and excavation methods, this technology has the potential to: – Work exponentially faster
 – Save dramatically in costs Our machines will employ high-power plasma torchesthat can vaporize and break up rock, clay, and obstacles into small fragments (known as spallation). |  | Seed | May 15, 2023 |  |
| Hotel Communication Network | Founded in 2008, with headquarters in Ottawa, Ontario, Canada, The Hotel Communication Network has built on years of research and development to provide an innovative high-value guest amenity that keeps each guest connected to their hotel, city and each other. |  | Series A | May 12, 2023 |  |

10 of 182 investments shown.

## Co-investors
- [Keiretsu Forum Northwest](https://shizune.co/investors/profile/keiretsu-forum-northwest) — VC Fund, 21 deals together
- [Keiretsu Forum](https://shizune.co/investors/profile/keiretsu-forum) — VC Fund, 19 deals together
- [K4 Forum Mumbai Network](https://shizune.co/investors/profile/k4-forum-mumbai-network) — VC Fund, 6 deals together
- [Band of Angels](https://shizune.co/investors/profile/band-of-angels) — VC Fund, 5 deals together
- [Mid Atlantic Bio Angels](https://shizune.co/investors/profile/mid-atlantic-bio-angels) — VC Fund, 4 deals together
- [Sectoral Asset Management](https://shizune.co/investors/profile/sectoral-asset-management) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Galaxy Interactive](https://shizune.co/investors/profile/galaxy-interactive) — VC Fund
- [Animoca Brands](https://shizune.co/investors/profile/animoca-brands-corporation) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund
- [APY Ventures](https://shizune.co/investors/profile/apy-ventures) — VC Fund
- [Boğaziçi Ventures](https://shizune.co/investors/profile/bo%C4%9Fazi%C3%A7i-ventures) — VC Fund

## Featured in investor lists
- [Medical Device Investors](https://shizune.co/investors/medical-device-investors)
- [Medical Device VC Funds](https://shizune.co/investors/medical-device-vc-funds)
- [Medical Device Investors in United States](https://shizune.co/investors/medical-device-investors-united-states)
- [Medical Device VC Funds in United States](https://shizune.co/investors/medical-device-vc-funds-united-states)
- [Art Investors in United States](https://shizune.co/investors/art-investors-united-states)
- [Art VC Funds in United States](https://shizune.co/investors/art-vc-funds-united-states)

## FAQ

### What does Keiretsu Capital invest in?

Keiretsu Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Convertible Note stage. Most of the 182 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Keiretsu Capital's check size?

Keiretsu Capital typically joins rounds of $700k–$2.5M at Seed and $1.2M–$12M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Keiretsu Capital participates in.

### How do I contact Keiretsu Capital?

Public channels for Keiretsu Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Keiretsu Capital?

The team at Keiretsu Capital includes Kevin Sterling (Keiretsu Capital Senior Advisor Network), Mary Jo Potter (General Partner) and Matthew Le Merle (Managing Partner & Co-founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co